|
| |
Follow-up (months) | Definition of outcome | Incidence of outcome |
|
| Angiolillo et al., 2007 [17] | 24 | Cardiovascular death, ACS, and stroke | 15.2 1st quartile |
| 12.2 2nd quartile |
| 12.2 3rd quartile |
| 37.7 4th quartile |
|
| Bliden et al., 2007 [18] | 1
12 | Death secondary to any cardiovascular cause, stroke,
myocardial infarction (ami), and target/nontarget vessel
revascularization | 23 (1 month FU)
50 (12 months FU) |
|
| Breet et al., 2010 [19] | 12 | All-cause death, nonfatal ami, stent thrombosis, and stroke | LTA 5 11.3 (DHPR) |
| 8.8 (HAPR) |
| 10.9 (HCPR) |
| 4.1 (NPR) |
| LTA 20 10.7 (DHPR) |
| 9.6 (HAPR) |
| 11.7 (HCPR) |
| 4.2 (NPR) |
|
| Buonamici et al., 2007 [2] | 6 | Stent thrombosis | 3.1 |
|
| Campo et al., 2010 [20] | 12 | All-cause death, nonfatal ami, and stroke | Full Responder (FR) 8.6 |
| Poor Responder (PR) 15.8 |
| ASA FR 10 PR 13 |
| Clop FR 5.9 PR 17.3 |
|
| Chiu et al., 2011 [21] | 24 | Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke | 10 |
|
| Collet et al., 2012 [7] | 1 | Stent thrombosis | 2 |
|
| Cuisset et al., 2006; 300 mg [22] | 1 | Cardiovascular death, nonfatal ami, stent thrombosis, and stroke | 12 |
| 33.3 HPR 0.5 NPR |
|
| Cuisset et al., 2006; 600 mg [22] | 1 | Cardiovascular death, nonfatal ami, stent thrombosis, and stroke | 4.1 |
| 27.2 HPR 0.008 NPR |
|
| Geisler et al., 2006 [23] | 3 | Cardiovascular death, nonfatal ami, and nonfatal stroke | 6.6 |
| 5.6 Adequate clopidogrel response |
| 22.7 Low clopidogrel response |
|
| Hochholzer et al., 2006 [24] | 1 | All-cause death, nonfatal ami, and percutaneous revascularization | 1.9 |
| 3.5 in upper quartile |
|
| Jin et al., 2013 [25] | 12 | Cardiovascular death, nonfatal ami, and nonfatal stroke | 11 |
|
| D.-W. Park et al., 2011 [26] | 12 |
Cardiac death and nonfatal ami | 1.4 |
| 0.9 Adequate clopidogrel response |
| 2.8 Low clopidogrel response |
|
| Ko et al., 2011 [27] | 1 | All-cause death, nonfatal ami, nonfatal stroke, and percutaneous revascularization | 8.6 |
|
| Marcucci et al., 2012 [28] | 12 | Cardiac death and nonfatal ami | 9.6 |
|
| Motoda et al., 2012 [29] | 12 | Cardiac death, nonfatal ami, stent thrombosis, and target vessel revascularization | 12 |
| 19 in HPR |
| 5.1 in NPR |
|
| K. W. Park et al., 2011 [30] | 24 | Cardiac death, nonfatal ami, nonfatal stroke, and urgent percutaneous revascularization | 14.6 HPR |
| 8.7 LPR |
|
| Park et al. (ACS), 2013 [31] | 72 | Cardiac death, nonfatal ami, nonfatal stroke, urgent percutaneous revascularization, and stent thrombosis | |
|
| Park et al. (Stable Angina), 2013 [31] | 72 | Cardiac death, nonfatal ami, nonfatal stroke, urgent percutaneous revascularization, and stent thrombosis | |
|
| Parodi et al., 2011 [32] | 1 | Cardiac death, nonfatal ami and percutaneous revascularization | 3 1st quartile |
| 5 2nd quartile |
| 10 3rd quartile |
| 20 4th quartile |
|
| Patti et al., 2008 [33] | 24 | All-cause death, nonfatal ami, unstable angina, and stroke | 13.3 HAPR |
| 9.9 LAPR |
|
| Pettersen et al., 2012 [34] | 6 | Cardiovascular death, nonfatal myocardial infarction, and stent thrombosis | 6.5 HPR |
| 1 LPR |
|
| Price et al., 2011 [9] | 1 | Stent thrombosis | 2.2 HPR |
| 0.2 LPR |
|
| Saia et al., 2013 [35] | 12 | All-cause death, ami, and urgent target vessel revascularization | |
|
| Sibbing et al., 2009 [36] | 1 | All-cause death, ami, and urgent target vessel revascularization | Abciximab/UFH: 9.4 HPR 6.7 LPR |
| Bivalirudin: 22.0 HPR 5.0 LPR |
|
| Sibbing et al., 2012 [37] | 12 | Acute coronary syndrome, stent thrombosis, stroke, death, and revascularization | 37.5 DHPR |
| 33.3 HCPR |
| 25.6 HAPR |
| 18.6 LPR |
|
| Siller-Matula et al., 2013 [38] | | Acute coronary syndrome, stent thrombosis, stroke, death, and revascularization | |
|
| Stone et al., 2013 [39] | 24 | All-cause death and myocardial infarction and stent thrombosis | 2.4 death |
| 3.9 mi |
| 1.3 ST |
|
